Abbott Laboratories
ABT
$105.90
-$0.02-0.02%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -17.45% | -34.57% | -39.67% | -24.87% | -1.95% |
| Total Depreciation and Amortization | -0.73% | -3.17% | -4.36% | -5.16% | -7.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -14.44% | 17.65% | 19.94% | 23.03% | 29.50% |
| Change in Net Operating Assets | -62.94% | -65.14% | 25.12% | 33.21% | -97.02% |
| Cash from Operations | -24.21% | -36.55% | -27.25% | -13.07% | -9.04% |
| Capital Expenditure | -23.92% | -15.50% | -10.65% | -1.49% | 5.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -380.23% | -- | -- |
| Divestitures | -16.67% | -16.67% | -70.15% | -64.18% | -64.18% |
| Other Investing Activities | -754.55% | -2.17% | 69.17% | 45.45% | 84.29% |
| Cash from Investing | -80.06% | -65.32% | -43.42% | 5.34% | 13.35% |
| Total Debt Issued | -57.41% | -77.08% | 1,100.00% | 483.33% | 1,250.00% |
| Total Debt Repaid | -231.74% | -61.28% | 96.80% | 95.60% | -198.81% |
| Issuance of Common Stock | 0.00% | -16.35% | -20.81% | -25.44% | -34.51% |
| Repurchase of Common Stock | 67.67% | 59.52% | 36.64% | 53.17% | -65.07% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.46% | -6.30% | -5.22% | -4.11% | -3.34% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 7.14% | 19.45% | 27.85% | 37.45% | -38.99% |
| Foreign Exchange rate Adjustments | 81.15% | 101.61% | 46.22% | -145.45% | -74.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,697.59% | -1,088.01% | -494.98% | 492.08% | -97.20% |
